| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ... New England journal of medicine 352 (10), 987-996, 2005 | 22344 | 2005 |
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the … R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ... The lancet oncology 10 (5), 459-466, 2009 | 8042 | 2009 |
| Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial A Malmström, BH Grønberg, C Marosi, R Stupp, D Frappaz, H Schultz, ... The lancet oncology 13 (9), 916-926, 2012 | 1356 | 2012 |
| European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of … R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ... Lancet Oncol 10 (5), 459-466, 2009 | 1004 | 2009 |
| European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas M Weller, M Van Den Bent, JC Tonn, R Stupp, M Preusser, ... The lancet oncology 18 (6), e315-e329, 2017 | 984 | 2017 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 944 | 2017 |
| Prediction of venous thromboembolism in cancer patients C Ay, D Dunkler, C Marosi, AL Chiriac, R Vormittag, R Simanek, ... Blood, The Journal of the American Society of Hematology 116 (24), 5377-5382, 2010 | 900 | 2010 |
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma AS Berghoff, B Kiesel, G Widhalm, O Rajky, G Ricken, A Wöhrer, ... Neuro-oncology 17 (8), 1064-1075, 2015 | 583 | 2015 |
| High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) C Ay, R Simanek, R Vormittag, D Dunkler, G Alguel, S Koder, G Kornek, ... Blood, The Journal of the American Society of Hematology 112 (7), 2703-2708, 2008 | 510 | 2008 |
| Meningioma C Marosi, M Hassler, K Roessler, M Reni, M Sant, E Mazza, C Vecht Critical reviews in oncology/hematology 67 (2), 153-171, 2008 | 510 | 2008 |
| Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study BG Baumert, ME Hegi, MJ van den Bent, A von Deimling, T Gorlia, ... The Lancet Oncology 17 (11), 1521-1532, 2016 | 486 | 2016 |
| Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) R Soffietti, U Abacioglu, B Baumert, SE Combs, S Kinhult, JM Kros, ... Neuro-oncology 19 (2), 162-174, 2017 | 477 | 2017 |
| 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 442 | 2019 |
| MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ... Clinical cancer research 21 (9), 2057-2064, 2015 | 364 | 2015 |
| MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome … P Bady, D Sciuscio, AC Diserens, J Bloch, MJ Van Den Bent, C Marosi, ... Acta neuropathologica 124, 547-560, 2012 | 333 | 2012 |
| Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients J THALER, C Ay, N Mackman, RM Bertina, A Kaider, C Marosi, NS Key, ... Journal of Thrombosis and Haemostasis 10 (7), 1363-1370, 2012 | 319 | 2012 |
| Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine A Becherer, G Karanikas, M Szabó, G Zettinig, S Asenbaum, C Marosi, ... European journal of nuclear medicine and molecular imaging 30, 1561-1567, 2003 | 306 | 2003 |
| EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force R Soffietti, P Cornu, JY Delattre, R Grant, F Graus, W Grisold, J Heimans, ... European journal of Neurology 13 (7), 674-681, 2006 | 294 | 2006 |
| Anti‐O6‐methylguanine‐methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its … M Preusser, R Charles Janzer, J Felsberg, G Reifenberger, MF Hamou, ... Brain pathology 18 (4), 520-532, 2008 | 280 | 2008 |
| Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study C Ay, D Dunkler, R Simanek, J Thaler, S Koder, C Marosi, C Zielinski, ... J Clin Oncol 29 (15), 2099-2103, 2011 | 256 | 2011 |
